Crossmark Global Holdings Inc. Has $6.02 Million Stock Position in Zoetis Inc. (NYSE:ZTS)

Crossmark Global Holdings Inc. boosted its position in Zoetis Inc. (NYSE:ZTS) by 13.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 36,936 shares of the company’s stock after buying an additional 4,248 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Zoetis were worth $6,018,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Ballentine Partners LLC increased its stake in shares of Zoetis by 3.0% in the fourth quarter. Ballentine Partners LLC now owns 12,151 shares of the company’s stock worth $1,980,000 after purchasing an additional 357 shares during the period. Martel Wealth Advisors Inc acquired a new stake in Zoetis in the 4th quarter valued at approximately $489,000. Sky Investment Group LLC increased its position in Zoetis by 5.7% in the 4th quarter. Sky Investment Group LLC now owns 22,264 shares of the company’s stock worth $3,627,000 after buying an additional 1,207 shares during the period. Cove Private Wealth LLC acquired a new position in shares of Zoetis during the fourth quarter worth approximately $647,000. Finally, UMB Bank n.a. boosted its position in shares of Zoetis by 0.9% in the fourth quarter. UMB Bank n.a. now owns 76,807 shares of the company’s stock valued at $12,514,000 after acquiring an additional 661 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of ZTS stock opened at $167.50 on Wednesday. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The stock’s fifty day simple moving average is $170.73 and its 200 day simple moving average is $179.95. Zoetis Inc. has a one year low of $144.80 and a one year high of $200.53. The firm has a market cap of $75.57 billion, a price-to-earnings ratio of 31.49, a P/E/G ratio of 2.55 and a beta of 0.89.

Zoetis (NYSE:ZTS) last announced its earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The firm’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter last year, the company posted $1.36 EPS. On average, analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Tuesday, January 21st. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a yield of 1.19%. Zoetis’s dividend payout ratio is 32.52%.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research reports. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. lifted their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Finally, Leerink Partners began coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price objective for the company. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $211.89.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.